Inactive Instrument

Celldex Therapeutics, Inc. Stock price Nasdaq

Equities

US15117B1035

Biotechnology & Medical Research

Sales 2024 * 3.39M Sales 2025 * 3.13M Capitalization 2.7B
Net income 2024 * -170M Net income 2025 * -203M EV / Sales 2024 * 714 x
Net cash position 2024 * 285M Net cash position 2025 * 372M EV / Sales 2025 * 745 x
P/E ratio 2024 *
-14.4 x
P/E ratio 2025 *
-12.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.65%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Celldex Therapeutics, Inc.

Managers TitleAgeSince
Founder 65 82-12-31
Founder 62 82-12-31
Director of Finance/CFO 53 09-03-31
Members of the board TitleAgeSince
Director/Board Member 91 08-02-29
Director/Board Member 58 22-06-15
Director/Board Member 78 96-12-31
More insiders
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Celldex Therapeutics, Inc.
  4. Stock Celldex Therapeutics, Inc. - Nasdaq